share_log

Exicure | 8-K: Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure | 8-K: Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure | 8-K：Exicure, Inc. 公布2023年第三季度财务业绩
美股sec公告 ·  05/16 16:52
Moomoo AI 已提取核心信息
On May 16, 2024, Exicure, Inc., a biotechnology company historically focused on nucleic acid therapies, reported its financial results for the third quarter ended September 30, 2023. The company disclosed a significant decrease in cash and cash equivalents, from $8.6 million at the end of 2022 to $0.9 million as of September 30, 2023, and further down to $0.2 million by April 30, 2024. Exicure highlighted the need for immediate additional funding to continue operations. Research and development expenses for the quarter were reported at $0, reflecting the cessation of all research and development activities following a restructuring announced in September 2022. General and administrative expenses remained relatively stable at $2.4 million. The net loss for the quarter was $5.3 million, a slight increase from the $5.2 million loss in the same period the previous year. The company's management expressed concerns about the ability to continue funding operations without substantial additional financing, which is needed imminently to pay expenses and explore strategic alternatives.
On May 16, 2024, Exicure, Inc., a biotechnology company historically focused on nucleic acid therapies, reported its financial results for the third quarter ended September 30, 2023. The company disclosed a significant decrease in cash and cash equivalents, from $8.6 million at the end of 2022 to $0.9 million as of September 30, 2023, and further down to $0.2 million by April 30, 2024. Exicure highlighted the need for immediate additional funding to continue operations. Research and development expenses for the quarter were reported at $0, reflecting the cessation of all research and development activities following a restructuring announced in September 2022. General and administrative expenses remained relatively stable at $2.4 million. The net loss for the quarter was $5.3 million, a slight increase from the $5.2 million loss in the same period the previous year. The company's management expressed concerns about the ability to continue funding operations without substantial additional financing, which is needed imminently to pay expenses and explore strategic alternatives.
2024年5月16日，历史上专注于核酸疗法的生物技术公司Exicure, Inc. 公布了截至2023年9月30日的第三季度财务业绩。该公司透露，现金及现金等价物大幅减少，从2022年底的860万美元降至2023年9月30日的90万美元，到2024年4月30日进一步下降至20万美元。Exicure强调需要立即提供额外资金以继续运营。该季度的研发费用报告为0美元，这反映了2022年9月宣布的重组后所有研发活动的停止。一般和行政费用保持相对稳定，为240万美元。该季度的净亏损为530万美元，较去年同期的520万美元亏损略有增加。该公司的管理层对在没有大量额外融资的情况下继续为运营提供资金的能力表示担忧，迫切需要这笔资金来支付费用和探索战略替代方案。
2024年5月16日，历史上专注于核酸疗法的生物技术公司Exicure, Inc. 公布了截至2023年9月30日的第三季度财务业绩。该公司透露，现金及现金等价物大幅减少，从2022年底的860万美元降至2023年9月30日的90万美元，到2024年4月30日进一步下降至20万美元。Exicure强调需要立即提供额外资金以继续运营。该季度的研发费用报告为0美元，这反映了2022年9月宣布的重组后所有研发活动的停止。一般和行政费用保持相对稳定，为240万美元。该季度的净亏损为530万美元，较去年同期的520万美元亏损略有增加。该公司的管理层对在没有大量额外融资的情况下继续为运营提供资金的能力表示担忧，迫切需要这笔资金来支付费用和探索战略替代方案。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息